These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 10368924

  • 1. Sex differences in stereospecificity of oracin reductases in rat in vitro and in vivo.
    Wsól V, Skálová L, Szotáková B, Trejtnar F, Kvasnicková E.
    Chirality; 1999; 11(5-6):505-9. PubMed ID: 10368924
    [Abstract] [Full Text] [Related]

  • 2. A comparison between stereospecificity of oracin reduction and stereoselectivity of oxidation of 11-dihydrooracin enantiomers in vitro in rat and guinea pig.
    Skálová L, Wsól V, Szotáková B, Kvasnicková E.
    Chirality; 1999; 11(5-6):510-5. PubMed ID: 10368925
    [Abstract] [Full Text] [Related]

  • 3. Stereospecific reduction of the original anticancer drug oracin in rat extrahepatic tissues.
    Szotáková B, Skálová L, Jílek P, Buchta V, Wsól V.
    J Pharm Pharmacol; 2003 Jul; 55(7):1003-11. PubMed ID: 12906758
    [Abstract] [Full Text] [Related]

  • 4. The main metabolic pathway of oracin, a new potential cytostatic drug, in human liver microsomes and cytosol: stereoselectivity of reoxidation of the principal metabolite 11-dihydrooracin to oracin.
    Wsól V, Szotáková B, Skálová L, Cepková H, Kvasnicková E.
    Enantiomer; 2000 Jul; 5(3-4):263-70. PubMed ID: 11126866
    [Abstract] [Full Text] [Related]

  • 5. Partial purification and characterization of a new human membrane-bound carbonyl reductase playing a role in the deactivation of the anticancer drug oracin.
    Skarydová L, Skarka A, Novotná R, Zivná L, Martin HJ, Wsól V, Maser E.
    Toxicology; 2009 Oct 01; 264(1-2):52-60. PubMed ID: 19635524
    [Abstract] [Full Text] [Related]

  • 6. Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man.
    Wsol V, Szotakova B, Martin HJ, Maser E.
    Toxicology; 2007 Sep 05; 238(2-3):111-8. PubMed ID: 17618725
    [Abstract] [Full Text] [Related]

  • 7. High-performance liquid chromatography study of stereospecific microsomal enzymes catalysing the reduction of a potential cytostatic drug, oracin. Interspecies comparison.
    Wsól V, Szotáková B, Kvasnicková E, Fell AF.
    J Chromatogr A; 1998 Feb 27; 797(1-2):197-201. PubMed ID: 9542111
    [Abstract] [Full Text] [Related]

  • 8. The novel anticancer drug oracin: different stereospecificity and cooperativity for carbonyl reduction by purified human liver 11beta-hydroxysteroid dehydrogenase type 1.
    Wsól V, Szotáková B, Skálová L, Maser E.
    Toxicology; 2004 May 03; 197(3):253-61. PubMed ID: 15033547
    [Abstract] [Full Text] [Related]

  • 9. Reduction of the potential anticancer drug oracin in the rat liver in-vitro.
    Szotáková B, Skálová L, Wsól V, Kvasniècková E.
    J Pharm Pharmacol; 2000 May 03; 52(5):495-500. PubMed ID: 10864136
    [Abstract] [Full Text] [Related]

  • 10. Stereochemical aspects of carbonyl reduction of the original anticancer drug oracin by mouse liver microsomes and purified 11beta-hydroxysteroid dehydrogenase type 1.
    Wsól V, Szotáková B, Skálová L, Maser E.
    Chem Biol Interact; 2003 Feb 01; 143-144():459-68. PubMed ID: 12604232
    [Abstract] [Full Text] [Related]

  • 11. Activity, stereospecificity, and stereoselectivity of microsomal enzymes in dependence on storage and freezing of rat liver samples.
    Skálová L, Szotáková B, Wsól V, Král R, Baliharová V, Lamka J.
    Chirality; 2000 Oct 01; 12(9):649-53. PubMed ID: 10984737
    [Abstract] [Full Text] [Related]

  • 12. Stereospecificity and stereoselectivity of flobufen metabolic profile in male rats in vitro and in vivo: phase I of biotransformation.
    Wsól V, Král R, Skálová L, Szotáková B, Trejtnar F, Flieger M.
    Chirality; 2001 Oct 01; 13(10):754-9. PubMed ID: 11746815
    [Abstract] [Full Text] [Related]

  • 13. Stereospecificity of flobufen metabolism in guinea pigs in vitro and in vivo: phase I of biotransformation.
    Kral R, Skalova L, Szotakova B, Babu YN, Wsol V.
    Chirality; 2004 Jan 01; 16(1):1-9. PubMed ID: 14628293
    [Abstract] [Full Text] [Related]

  • 14. Central composite design as a powerful optimisation technique for enantioresolution of the rac-11-dihydrooracin--the principal metabolite of the potential cytostatic drug oracin.
    Wsól V, Fell AF.
    J Biochem Biophys Methods; 2002 Dec 31; 54(1-3):377-90. PubMed ID: 12543513
    [Abstract] [Full Text] [Related]

  • 15. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells.
    Gavelová M, Hladíková J, Vildová L, Novotná R, Vondrácek J, Krcmár P, Machala M, Skálová L.
    Chem Biol Interact; 2008 Oct 22; 176(1):9-18. PubMed ID: 18755171
    [Abstract] [Full Text] [Related]

  • 16. Warfarin: stereochemical aspects of its metabolism in vivo in the rat.
    Pohl LR, Bales R, Trager WF.
    Res Commun Chem Pathol Pharmacol; 1976 Oct 22; 15(2):233-56. PubMed ID: 981784
    [Abstract] [Full Text] [Related]

  • 17. Biotransformation of flobufen enantiomers in ruminant hepatocytes and subcellular fractions.
    Skálová L, Szotáková B, Lamka J, Král R, Vanková I, Baliharová V, Wsól V.
    Chirality; 2001 Oct 22; 13(10):760-4. PubMed ID: 11746816
    [Abstract] [Full Text] [Related]

  • 18. Use of chiral liquid chromatography for the evaluation of stereospecificity in the carbonyl reduction of potential benzo[c]fluorene antineoplastics benfluron and dimefluron in various species.
    Kucera R, Nobilis M, Skálová L, Szotáková B, Císar P, Jira T, Klimes J, Wsól V.
    J Pharm Biomed Anal; 2005 Apr 29; 37(5):1049-57. PubMed ID: 15862685
    [Abstract] [Full Text] [Related]

  • 19. High-performance liquid chromatographic assay for the separation and characterization of metabolites of the potential cytostatic drug oracine.
    Wsól V, Kvasnicková E, Szotáková B, Hais IM.
    J Chromatogr B Biomed Appl; 1996 May 31; 681(1):169-75. PubMed ID: 8798926
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics and metabolism of a cysteinyl leukotriene-1 receptor antagonist from the heterocyclic chromanol series in rats: in vitro-in vivo correlation, gender-related differences, isoform identification, and comparison with metabolism in human hepatic tissue.
    Kuperman AV, Kalgutkar AS, Marfat A, Chambers RJ, Liston TE.
    Drug Metab Dispos; 2001 Nov 31; 29(11):1403-9. PubMed ID: 11602515
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.